Literature DB >> 20545040

Focus on kidney cancer: Significant overall survival advantage for RCC patients treated with autologous tumor lysate vaccine.

Lisa Hutchinson.   

Abstract

Entities:  

Year:  2010        PMID： 20545040     DOI： 10.1038/nrurol.2010.71

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting.

Authors:  Matthias May; Sabine Brookman-May; Bernd Hoschke; Christian Gilfrich; Friederike Kendel; Susann Baxmann; Stefan Wittke; Stephan T Kiessig; Kurt Miller; Manfred Johannsen
Journal:  Cancer Immunol Immunother       Date:  2009-10-30       Impact factor: 6.968
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.